glp-1 drugs news today weight loss leave users low on key nutrients, study finds Market Overview: GLP-1 Agonists and

Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower ...

Experts say more education and awareness are needed.

A recent study, published in the Journal of Pharmacy and Pharmacology Research, sugges

Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results

Smriti Choudhary, MD, at Primary Care Center of Clear Lake.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs